Kuriyama M, Abrahamsson P A, Imai K, Akimoto S, Deguchi N, Shichiri Y, Sugiyama Y, Niwa T, Inoue T
Department of Urology, Gifu University School of Medicine, Japan.
Scand J Urol Nephrol. 2001 Feb;35(1):5-10. doi: 10.1080/00365590151030660.
The clinical utility of the determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex (PSA-ACT) for the diagnosis of prostate cancer, especially in cases in the diagnostic gray zone, is still unclear.
With the use of a newly approved enzyme immunoassay for the detection of PSA-ACT, 907 sera, including those from non-urological benign and malignant diseases, were analysed.
Serum values of PSA-ACT in non-prostate cancer males increased according to age from the 40s to 70s. The serum values were high only in the patients with prostatic diseases and, in prostate cancer patients, the values became high as the clinical stage progressed. By receiver-operating characteristic analysis significantly better results in PSA-ACT than total PSA were observed. In the group with a total PSA of 2-20 ng/ml, the detection of PSA-ACT showed better results, although not significantly so, than the free-to-total PSA ratio.
The detection of PSA-ACT showed a high clinical utility in the diagnosis of prostate cancer. Therefore, it may replace total PSA determination.
血清前列腺特异性抗原-α1-抗糜蛋白酶复合物（PSA-ACT）测定在前列腺癌诊断中的临床实用性，尤其是在诊断灰色地带的病例中，仍不明确。
使用一种新批准的用于检测PSA-ACT的酶免疫测定法，分析了907份血清，包括来自非泌尿外科良性和恶性疾病患者的血清。
非前列腺癌男性的PSA-ACT血清值从40多岁到70多岁随年龄增长而升高。血清值仅在前列腺疾病患者中较高，在前列腺癌患者中，随着临床分期进展而升高。通过受试者工作特征分析，观察到PSA-ACT的结果明显优于总PSA。在总PSA为2-20 ng/ml的组中，PSA-ACT的检测结果虽未显著优于游离PSA与总PSA比值，但也显示出较好的结果。
PSA-ACT的检测在前列腺癌诊断中显示出较高的临床实用性。因此，它可能取代总PSA测定。
